AstraZeneca starts trial of Covid-19 antibody treatment | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Thursday
November 30, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
THURSDAY, NOVEMBER 30, 2023
AstraZeneca starts trial of Covid-19 antibody treatment

Coronavirus chronicle

Reuters
25 August, 2020, 04:00 pm
Last modified: 25 August, 2020, 04:02 pm

Related News

  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • AstraZeneca Covid drug neutralises Omicron sub-variants in study
  • 98% people developed antibodies after 2nd Covid jab
  • Short AstraZeneca shelf life complicates Covid vaccine rollout to world's poorest

AstraZeneca starts trial of Covid-19 antibody treatment

The London-listed firm, already among the leading players in the global race to develop a successful vaccine, said the study would evaluate if AZD7442, a combination of two monoclonal antibodies (mAbs), was safe and tolerable in up to 48 healthy participants between the ages of 18 and 55 years

Reuters
25 August, 2020, 04:00 pm
Last modified: 25 August, 2020, 04:02 pm
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London, April 28, 2014. REUTERS/Stefan Wermuth/File Photo
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London, April 28, 2014. REUTERS/Stefan Wermuth/File Photo

British drugmaker AstraZeneca has begun testing an antibody-based cocktail for the prevention and treatment of Covid-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.

The London-listed firm, already among the leading players in the global race to develop a successful vaccine, said the study would evaluate if AZD7442, a combination of two monoclonal antibodies (mAbs), was safe and tolerable in up to 48 healthy participants between the ages of 18 and 55 years.

If the UK-based early-stage trial, which has dosed its participants, shows AZD7442 is safe, AstraZeneca said it would proceed to test it as both a preventative treatment for Covid-19 and a medicine for patients who have it, in larger, mid-to-late-stage studies.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

AstraZeneca shares were up about 1 percent at 87 pounds ($114) in early trading.

Development of mAbs to target the virus, an approach already being tested by Regeneron, ELi Lilly, Roche and Molecular Partners, has been endorsed by leading scientists.

mAbs mimic natural antibodies generated in the body to fight off infection and can be synthesised in the laboratory to treat diseases in patients. Current uses include treatment of some types of cancers.

US infectious diseases expert Anthony Fauci has called them "almost a sure bet" against Covid-19, and AstraZeneca in June received $23.7 million in funding from US government agencies to advance development of antibody-based treatments for Covid-19.

"This combination of antibodies, coupled to our proprietary half-life extension technology, has the potential to improve both the effectiveness and durability of use in addition to reducing the likelihood of viral resistance," said Astra's executive vice president of biopharmaceuticals R&D Mene Pangalos.

Though vaccines are at the heart of the long-term fight against the pandemic, alternative treatments are also being advanced, and the United States on Sunday authorized use of recovered Covid-19 patients' plasma to treat those who are ill.

The Financial Times reported at the weekend that President Donald Trump's administration was considering a fast-tracked approval of AstraZeneca's Covid-19 vaccine before November's elections.

AstraZeneca / Antibody Test

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BNP Vice Chairman Shahjahan Omar. Photo: UNB
    Shahjahan Omar walks out of jail, leaves BNP, submits nomination for Jhalakathi-1 as AL candidate
  • File Photo of Prime Minister Sheikh Hasina
    JS polls: 7 candidates set to compete against PM Hasina for Gopalganj-3 seat
  • Photo: Facebook.
    AL not worried about election observers: Quader

MOST VIEWED

  • TBS file photo
    Over 50 lakh Bangladeshis living abroad: Census
  • Despite some positives like, changes in wordings the major things workers demand have not been reflected in the amendments. Photo: TBS
    Bangladesh could be target of US labour policy, warns Washington mission
  • Taka appreciated officially, market reacts quite opposite
    Taka appreciated officially, market reacts quite opposite
  • Mominul Islam. File Photo: Courtesy
    IPDC CEO Mominul to step down after 4 terms
  • Only approved appraisers to assess loan collateral: Cenbank 
    Only approved appraisers to assess loan collateral: Cenbank 
  • File Photo: Reuters
    Reserves now at $19.52 billion: Bangladesh Bank

Related News

  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • AstraZeneca Covid drug neutralises Omicron sub-variants in study
  • 98% people developed antibodies after 2nd Covid jab
  • Short AstraZeneca shelf life complicates Covid vaccine rollout to world's poorest

Features

Photo: Nayem Ali

Falling into brown

4h | Features
Illustartion:TBS

Low tax-GDP ratio: Reluctant taxpayers, faulty structure

11h | Panorama
Illustration: TBS

I am afraid even to post a thank you note on Facebook: Khadija

11h | Panorama
Sketch: TBS

Towards a brighter tomorrow: India's G20 presidency and the dawn of a new multilateralism

11h | Panorama

More Videos from TBS

How much aid has entered Gaza?

How much aid has entered Gaza?

54m | TBS World
The maximum interest rate for NBFI loans is 13.18%

The maximum interest rate for NBFI loans is 13.18%

1h | TBS Economy
Loan disbursements through agent banking rise 60%

Loan disbursements through agent banking rise 60%

4h | TBS Economy
First transatlantic flight using 100% green fuels to take off

First transatlantic flight using 100% green fuels to take off

8h | TBS Stories
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]